{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:10:07Z","timestamp":1792062607672,"version":"4.4.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.jbspin.2006.01.007","type":"journal-article","created":{"date-parts":[[2006,3,24]],"date-time":"2006-03-24T12:40:16Z","timestamp":1143204016000},"page":"388-395","source":"Crossref","is-referenced-by-count":120,"title":["Methotrexate therapy for\u00a0rheumatoid arthritis: clinical practice guidelines based on\u00a0published evidence and\u00a0expert opinion"],"prefix":"10.1016","volume":"73","author":[{"given":"Stephan","family":"Pavy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francis","family":"Maillefert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cantagrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Combe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9-Marc","family":"Flipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Goupille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Le Lo\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pu\u00e9chal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Tebib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wendling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Dougados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2006.01.007_bib1","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1056\/NEJMra040226","article-title":"Therapeutic strategies for rheumatoid arthritis","volume":"350","author":"O\u2019Dell","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbspin.2006.01.007_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/art.10148","article-title":"Guidelines for the management of rheumatoid arthritis 2002 update","volume":"46","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib3","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2006.01.007_bib4","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.1780280702","article-title":"Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial","volume":"28","author":"Williams","year":"1985","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbspin.2006.01.007_bib6","doi-asserted-by":"crossref","first-page":"999","DOI":"10.7326\/0003-4819-114-12-999","article-title":"Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis: a randomized, double-blind study","volume":"114","author":"Jeurissen","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbspin.2006.01.007_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.1780360507","article-title":"The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin","volume":"36","author":"Weinblatt","year":"1993","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2006.01.007_bib9","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group","volume":"353","author":"Mottonen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2006.01.007_bib10","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2006.01.007_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jbspin.2006.01.007_bib12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib13","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1136\/ard.2004.023697","article-title":"EULAR standardised operating procedures for the elaboration, evaluation, dissemination and implementation of recommendations endorsed by the EULAR standing committees","volume":"63","author":"Dougados","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2006.01.007_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jbspin.2004.10.010","article-title":"Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion","volume":"73","author":"Pham","year":"2005","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.jbspin.2006.01.007_bib15","article-title":"Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion","volume":"73","author":"Pham","year":"2006","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.jbspin.2006.01.007_bib16","article-title":"Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion","volume":"73","author":"Gossec","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2006.01.007_bib17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bmj.318.7183.593","article-title":"Clinical guidelines: developing guidelines","volume":"318","author":"Shekelle","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2006.01.007_bib18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/rheumatology\/32.8.751","article-title":"Methotrexate\u2014the relationship between dose and clinical effect","volume":"32","author":"Seideman","year":"1993","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib19","first-page":"313","article-title":"Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis","volume":"16","author":"Furst","year":"1989","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.57.2.110","article-title":"Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients","volume":"57","author":"Bressolle","year":"1998","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2006.01.007_bib21","first-page":"1356","article-title":"Methotrexate kinetics in rheumatoid arthritis: is there an interaction with nonsteroidal antiinflammatory drugs?","volume":"15","author":"Ahern","year":"1988","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib22","first-page":"218","article-title":"The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis","volume":"22","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/art.20167","article-title":"Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial","volume":"50","author":"Lambert","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib24","first-page":"1845","article-title":"A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing","volume":"20","author":"Jundt","year":"1993","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib25","first-page":"645","article-title":"Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis","volume":"31","author":"Hoekstra","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/rheumatology\/36.1.86","article-title":"Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis","volume":"36","author":"Hamilton","year":"1997","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/rheumatology\/keg246","article-title":"Parenteral methotrexate should be given before biological therapy","volume":"42","author":"Bingham","year":"2003","journal-title":"Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/rheumatology\/keh471","article-title":"Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease","volume":"44","author":"Moitra","year":"2005","journal-title":"Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib29","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ard.2003.011593","article-title":"Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis","volume":"63","author":"Wegrzyn","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2006.01.007_bib30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1136\/ard.61.8.756","article-title":"Relapse of rheumatoid arthritis after substitution of oral for parenteral administration of methotrexate","volume":"61","author":"Rozin","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2006.01.007_bib31","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/art.20019","article-title":"Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib33","unstructured":"Breedveld FC, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Perez JL, et al. Early Treatment of Rheumatoid Arthritis (RA) With Adalimumab (HUMIRA\u00ae) Plus Methotrexate vs. Adalimumab Alone or Methotrexate Alone: The PREMIER Study. 68th Annual Scientific Meeting of the American College of Rheumatology. October 16-21, 2004 in San Antonio, Texas. Poster Presentation (Presentation Number L5)."},{"key":"10.1016\/j.jbspin.2006.01.007_bib34","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/ard.2004.035030","article-title":"Increase in methotrexate dose in rheumatoid arthritis patients with an inadequate response to infliximab","volume":"64","author":"Ornetti","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2006.01.007_bib35","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib36","first-page":"459","article-title":"Significant changes in serum AST across hepatic histological biopsy grades: prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis","volume":"23","author":"Kremer","year":"1996","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib37","first-page":"375","article-title":"Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis","volume":"22","author":"Hagiyama","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib38","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2006.01.007_bib39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q","article-title":"Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient","volume":"44","author":"Ito","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib40","first-page":"2037","article-title":"Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy","volume":"25","author":"Narvaez","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/0003-4819-112-5-381","article-title":"Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy","volume":"112","author":"Flowers","year":"1990","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbspin.2006.01.007_bib42","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/rheumatology\/keh668","article-title":"Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon","volume":"44","author":"Nissen","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2006.01.007_bib43","first-page":"363","article-title":"Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis","volume":"18","author":"Mok","year":"2000","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","article-title":"Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities","volume":"64","author":"Yazici","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2006.01.007_bib45","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/art.1780390214","article-title":"Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis","volume":"39","author":"Gutierrez-Urena","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib46","first-page":"477","article-title":"Pancytopenia and severe cytopenia induced by low-dose methotrexate. Eight case-reports and a review of one hundred cases from the literature (with twenty-four deaths)","volume":"62","author":"Berthelot","year":"1995","journal-title":"Rev. Rhum. Engl. Ed"},{"key":"10.1016\/j.jbspin.2006.01.007_bib47","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group","volume":"127","author":"Alarcon","year":"1997","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbspin.2006.01.007_bib48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/keg466","article-title":"Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis","volume":"43","author":"Saravanan","year":"2004","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2006.01.007_bib49","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/thx.47.8.628","article-title":"Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports","volume":"47","author":"Hargreaves","year":"1992","journal-title":"Thorax"},{"key":"10.1016\/j.jbspin.2006.01.007_bib50","first-page":"2299","article-title":"Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis","volume":"24","author":"Ohosone","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib51","first-page":"1043","article-title":"The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis","volume":"22","author":"Golden","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib52","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0049-0172(87)90021-7","article-title":"Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate","volume":"16","author":"Carson","year":"1987","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib53","first-page":"1164","article-title":"Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature","volume":"14","author":"Searles","year":"1987","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib54","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/art.1780401016","article-title":"Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review","volume":"40","author":"Kremer","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib55","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"2","author":"Ortiz","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jbspin.2006.01.007_bib56","first-page":"1078","article-title":"Concurrent use of folinic acid and methotrexate in rheumatoid arthritis","volume":"15","author":"Hanrahan","year":"1988","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib57","first-page":"1158","article-title":"Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis","volume":"17","author":"Buckley","year":"1990","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.1780330102","article-title":"The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis","volume":"33","author":"Morgan","year":"1990","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib59","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.50.12.913","article-title":"Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid","volume":"50","author":"Joyce","year":"1991","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbspin.2006.01.007_bib60","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/art.1780360609","article-title":"Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial","volume":"36","author":"Shiroky","year":"1993","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib61","first-page":"950","article-title":"Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8-week randomized placebo controlled trial","volume":"20","author":"Weinblatt","year":"1993","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jbspin.2006.01.007_bib62","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","article-title":"Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial","volume":"121","author":"Morgan","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jbspin.2006.01.007_bib63","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7","article-title":"Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study","volume":"44","author":"van Ede","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbspin.2006.01.007_bib64","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/rheumatology\/39.10.1102","article-title":"Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?","volume":"39","author":"Griffith","year":"2000","journal-title":"Rheumatology"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X06000583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X06000583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T15:20:25Z","timestamp":1547738425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X06000583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S1297319X06000583"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2006.01.007","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}